文献速递病毒性肝炎

丙型肝炎病毒感染中肝病分期临床与成本效果:微观模拟研究

Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

本研究采用终身微观模拟,比较美国健康中心慢性HCV成人五种纤维化分期策略的临床结局与成本效果。仅FIB-4策略临床结局最佳,治愈87.7%、肝硬化8.7%、肝相关死亡4.6%,ICER为每获得1个QALY 12869美元;TE策略结局更差且成本更高,仅在无失访时具成本效果。

要点

  • 仅FIB-4策略治愈87.7%、肝硬化8.7%、肝相关死亡4.6%,优于含TE的各策略。
  • 仅FIB-4策略相比无分期不治疗,ICER为每获得1个QALY 12869美元。
  • TE策略仅在无失访时具成本效果;不应延迟治疗等待TE分期。

核心结论

  • 仅FIB-4分期可获得最佳临床结局并具成本效果;慢性HCV治疗不应延迟等待TE纤维化分期。

研究设计与样本

  • 终身微观模拟研究,模拟在美国健康中心接受照护的慢性HCV成人,比较五种纤维化分期策略。
  • 五种策略:不检测不治疗(对照)、仅间接血清生物标志物FIB-4、仅瞬时弹性成像(TE)、序贯法(全部FIB-4,FIB-4中间值1.45-3.25者仅做TE)、全部同时做两种检测。
  • 采用文献来源的失访率及2021年医疗补助支付方视角与成本。

主要发现

  • 仅FIB-4策略:治愈87.7%、发生肝硬化8.7%、肝相关死亡4.6%。
  • TE策略:治愈58.5%-76.6%、发生肝硬化16.8%-29.4%、肝相关死亡11.6%-22.6%。
  • 所有TE策略临床结局更差且每QALY成本更高;仅FIB-4相比不检测不治疗,ICER为每获得1个QALY 12869美元。
  • 失访驱动上述结果:TE策略仅在无失访时具成本效果。
  • 在即时HCV检测治疗场景中,不做任何分期直接治疗最具临床与成本效果。

临床怎么用

  • 作者结论认为仅FIB-4分期可获得最佳临床结局并具成本效果。
  • 作者结论认为慢性HCV治疗不应延迟等待TE纤维化分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver disease assessment is a key aspect of chronic hepatitis C virus (HCV) infection pre-treatment evaluation but guidelines differ on the optimal testing modality given trade-offs in availability and accuracy. We compared clinical outcomes and cost-effectiveness of common fibrosis staging strategies. METHODS: We simulated adults with chronic HCV receiving care at US health centers through a lifetime microsimulation across five strategies: (1) no staging or treatment (comparator), (2) indirect serum biomarker testing (Fibrosis-4 index [FIB-4]) only, (3) transient elastography (TE) only, (4) staged approach: FIB-4 for all, TE only for intermediate FIB-4 scores (1.45-3.25), and (5) both tests for all. Outcomes included infections cured, cirrhosis cases, liver-related deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used literature-informed loss to follow-up (LTFU) rates and 2021 Medicaid perspective and costs. RESULTS: FIB-4 alone generated the best clinical outcomes: 87.7% cured, 8.7% developed cirrhosis, and 4.6% had liver-related deaths. TE strategies cured 58.5%-76.6%, 16.8%-29.4% developed cirrhosis, and 11.6%-22.6% had liver-related deaths. All TE strategies yielded worse clinical outcomes at higher costs per QALY than FIB-4 only, which had an ICER of $12 869 per QALY gained compared with no staging or treatment. LTFU drove these findings: TE strategies were only cost-effective with no LTFU. In a point-of-care HCV test-and-treat scenario, treatment without any staging was most clinically and cost-effective. CONCLUSIONS: FIB-4 staging alone resulted in optimal clinical outcomes and was cost-effective. Treatment for chronic HCV should not be delayed while awaiting fibrosis staging with TE.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Epstein RL, Munroe S, Taylor LE, et al. Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study. Clin Infect Dis. 2025. PMID: 39535186. doi:10.1093/cid/ciae485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。